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Abstract
Introduction:  While  cardiac  amyloidosis  (CA)  is a rare  systemic  disease  characterized  by
extracellular  deposition  of  protein-derived  fibrils,  hypertrophic  cardiomyopathy  (HCM)  is
histopathologically  characterized  by  myocyte  hypertrophy  and  disarray,  interstitial  fibrosis,  and
small intramural  coronary  arteriole  dysplasia.  The  aim  of  the present  study  was  to  compare  left
atrial (LA)  volumetric  and  functional  characteristics  between  light-chain  (AL)  CA  and  HCM  by
three-dimensional  (3D) speckle-tracking  echocardiography  (STE).
Methods:  The  AL-CA  group  initially  consisted  of  17  patients  with  AL-CA,  but  one  patient  was
excluded due  to  inadequate  image  quality,  and  so  the  study  population  consisted  of  16  patients
(mean age:  64.0±9.6  years,  five  men).  Their  results  were  compared  with  data  on 20  age-
matched HCM  patients  (mean  age:  59.8±5.2  years,  10  men)  and on 16  age-matched  healthy
controls (mean  age:  58.2±7.2  years,  six  men).  Complete  two-dimensional  Doppler  echocardi-
ography  and  3D-STE  were  performed  in all  cases.
Results:  Significantly  increased  LA  volumes  were  observed  in  both  AL-CA  and  HCM  compared
with the  control  group.  Only  active  atrial  emptying  fraction  was  found  to  be significantly  reduced
in AL-CA  patients  compared  to  controls.  Peak  global  and  mean  segmental  circumferential,
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longitudinal  and area  strains  showed  significant  reductions  in AL-CA  patients  compared  with
controls, but  only  peak  mean  segmental  longitudinal  strain  differed  significantly  between  HCM
patients  and  controls.  While  no  differences  were  demonstrated  in  global  and  mean  segmen-
tal strain  at atrial  contraction  between  HCM  patients  and  controls,  AL-CA  patients  showed
reductions in certain  strain  parameters  compared  to  controls  and  HCM  patients.
Conclusions:  Different  patterns  of  LA  functional  characteristics  were  demonstrated  in AL-CA
and HCM  patients  by  3D-STE.
©  2017  Sociedade  Portuguesa  de Cardiologia.  Published  by  Elsevier  Espan˜a, S.L.U.  All  rights
reserved.
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Disfunc¸ão da aurícula  esquerda  na amiloidose  cardíaca  de cadeias  leves  e  na
miocardiopatia  hipertrófica  --  Uma  análise  comparativa  por ecocardiograma
tridimensional  com  speckle  tracking  do  estudo  MAGYAR-Path
Resumo
Introduc¸ão: A  amiloidose  cardíaca  (CA)  é uma  doenc¸a  sistémica  rara,  caracterizada  pela
deposic¸ão extracelular  de  fibrilhas  derivadas  das  proteínas;  por  outro  lado,  a  miocardiopa-
tia hipertrófica  (HCM)  é caracterizada  do  ponto  de vista  histopatológico  por  hipertrofia  e
desorganizac¸ão dos  miócitos,  fibrose  intersticial  e displasia  das  pequenas  arteríolas  coronárias
intramurais.  No presente  estudo  fomos  comparar  as  características  volumétricas  e funcionais
da aurícula  esquerda  (AE)  entre  a  CA  de cadeias  leves  (AL)  e a  HCM  com  ecocardiografia
speckle-tracking  tridimensional  (3DSTE).
Métodos:  A populac¸ão  do estudo  foi  constituída  por  17  doentes  com  AL-CA,  foi  excluído  um
doente por  deficiente  qualidade  de imagem.  Desse  modo,  o  grupo  final  de  AL-CA  consistiu
em 16  doentes  (média  de 64,0  ± 9,6  anos,  cinco  homens).  Os  resultados  desse  grupo  foram
comparados com  os de  20  doentes  com  HCM  emparelhados  por  idade  (idade  média:  59,8  ±
5,2 anos,  10  homens)  e com  16  controlos  saudáveis  igualmente  emparelhados  por  idade  média:
58,2 ± 7,2 anos,  seis  homens).  Em  todos  os  doentes  foi feito  ecocardiograma  Doppler  bidimen-
sional e 3DSTE.
Resultados:  Os volumes  da AE  foram  significativamente  maiores  nos  doentes  com  AL-CA  e  com
HCM comparados  com  o  grupo  controlo.  Apenas  a  frac¸ão de esvaziamento  auricular  ativo  foi
significativamente  mais  baixa  nos  doentes  com  AL-CA  em  comparac¸ão com  o  grupo  de controlo.
Apesar  de  os  strains  de  pico  e médio  segmentares,  circunferenciais,  longitudinais  e em  área
serem significativamente  mais  baixos  nos  doentes  com  AL-CA  por  comparac¸ão com  o grupo
controlo,  apenas  o  strain  longitudinal  segmentar  médio  de  pico  foi  significativamente  diferente
entre os doentes  com  HCM  e os  do  grupo  de controlo.  Apesar  de não  ter  sido  possível  demons-
trar diferenc¸as  no  strain  segmentar  global  e médio  entre  os  doentes  com  HCM e  o grupo  de
controlo,  no caso  dos  doentes  com  AL-CA  observou-se  reduc¸ão  em  alguns  parâmetros  de strain
por comparac¸ão quer  com  o  grupo  de doentes  com  HCM  quer  com  o  grupo  de controlo.
Conclusão:  Foi  possível  demonstrar  a  presenc¸a de  diferentes  padrões  funcionais  da  AE  por  3DSTE
em doentes  com  amiloidose  cardíaca  e miocardiopatia  hipertrófica.
© 2017  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
Introduction
While  cardiac  amyloidosis  (CA)  is  a rare  systemic  disease
characterized  by extracellular  deposition  of  protein-derived
fibrils,1 hypertrophic  cardiomyopathy  (HCM)  is a  relatively
common  genetic  cardiac  disease  histopathologically  charac-
terized  by  myocyte  hypertrophy  and  disarray,  interstitial
fibrosis,  and  small  intramural  coronary  arteriole  dysplasia.2
CA and  HCM  are both  known  to  be  associated  with  left atrial
(LA)  dysfunction.  Three-dimensional  (3D)  speckle-tracking
echocardiography  (STE)  has  been  demonstrated  to  have
unique  potential  for  detailed  ventricular  and  atrial  volumet-
ric  and functional  analysis.3 The  specific  aim  of  this  study
was  to  compare  volumetric  and  functional  characteristics
of  the left atrium  between  light-chain  (AL)  CA and  HCM  by
3D-STE.
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Methods
Subjects
The  AL-CA  group  initially  consisted  of  17  patients  with
AL-CA,  but  one  patient  was  excluded  due  to  inadequate
image  quality,  and so the  study  population  consisted  of
16  patients  (mean  age:  64.0±9.6  years,  five  men).  Their
results  were  compared  with  data  on 20  age-matched  HCM
patients  (mean  age:  59.8±5.2  years,  10  men)  and  on  16  age-
matched  healthy  controls  (mean  age:  58.2±7.2  years,  six
men).  The  diagnosis  of  AL-CA  was  confirmed  by biopsy  in all
CA  cases.  The  first  positive  biopsy  site was  the myocardium
in  four  cases,  bone  marrow  in three,  the duodenum  in  one,
the  salivary  gland  in one,  the  colon  in one,  the  rectum
in  one,  the  kidney  in  four and skin and subcutaneous  tis-
sue  in  three  cases (there  were  2  confirmation  sites  in 2
patients).  AL  amyloidosis  was  diagnosed  in patients  with
multiple  myeloma  in 12  cases,  with  plasma  cell  dyscrasia
in  one  case,  with  marginal  zone  lymphoma  in  one  case  and
with  nephrotic  syndrome  in  two  cases.  In these  patients,  in
whom  the  histopathological  report  confirmed  the  diagnosis
of  AL  amyloidosis,  two-dimensional  (2D) echocardiography
was  performed.  If cardiac  involvement  with  AL amyloido-
sis  was  suspected  according  to  the  data  below,  3D-STE  was
performed.  AL-CA  was  defined  in accordance  with  current
consensus  criteria  and  practice.4,5 Current  guidelines  were
also  used  for  diagnosis of  HCM.6 Hypertrophy  proved  to
be  asymmetric  and septally  located  in all HCM patiens.
Healthy  subjects  met  the following  criteria:  no  history
of  cardiac  symptoms,  hypertension,  diabetes  or  hyperc-
holesterolemia,  not  under  medication,  and  normal  physical
examination,  electrocardiogram  (ECG)  and  echocardiogram.
Complete  2D  Doppler  echocardiography  with  3D-STE-derived
data  acquisition  were  performed  in all  patients  and  healthy
subjects.  The  results  are included  in the Motion  Analy-
sis  of  the  heart  and  Great  vessels bY three-dimensionAl
speckle-tRacking  echocardiography  in  Pathological  cases
(MAGYAR-Path)  study  (‘Magyar’  means  ‘Hungarian’  in the
Hungarian  language),  carried out to  examine  the  diagnos-
tic  and  prognostic  value  of 3D-STE-derived  parameters  in
different  disorders.  Informed  consent  was  obtained  from
all  subjects,  the study  protocol  conformed  to  the eth-
ical  guidelines  of  the  1975  Declaration  of Helsinki,  and
the  institution’s  human  research  committee  approved  the
study.7
Two-dimensional echocardiography
A  commercially  available  ultrasound  system  (Toshiba
ArtidaTM, Toshiba  Medical  Systems,  Tokyo,  Japan)  equipped
with  a  broadband  (1-5 MHz)  PST-30SBP  phased-array  trans-
ducer  was  used  for standard  transthoracic  echocardio-
graphic  examinations.  Measurements  of  left  ventricular  (LV)
dimensions,  volumes  and  ejection  fraction  were  obtained
in  accordance  with  the recommendations  of the  Ameri-
can  Society  of  Echocardiography.8 The  degree  of mitral
regurgitation  (MR)  was  graded  visually  by  color  Doppler
echocardiography.
Three-dimensional  speckle-tracking
echocardiography
During  the  same  echocardiographic  examination,
3D  datasets  were  acquired in  apical  view  using  a  commer-
cially  available  1-4  MHz  PST-25SX  matrix-array  transducer
(Toshiba  Medical  Systems,  Tokyo,  Japan).3 During  end-
expiratory  breath-hold  and  six  ECG-gated  beats,  six
wedge-shaped  subvolumes  were  acquired  to create  the
LV  full  volume.  Off-line  analysis  of  the  3D datasets  was
performed  using  3D  Wall  Motion  Tracking  software,  ver-
sion  2.5  (Toshiba  Medical  Systems,  Tokyo,  Japan).  Apical
2-chamber  (AP2CH),  4-chamber  (AP4CH),  and  short-axis
views  at  different  levels  of the left  atrium  (basal,  mid,
and  superior)  were automatically  selected  at end-diastole
(Figure  1).  Non-foreshortened  AP2CH  and AP4CH  views
were  determined  by  finding  the  largest  long-axis  LA
dimensions,  then  the mitral  annulus  and  the  LA apex
were  marked  manually.  The  LA appendage  and pulmonary
veins  were  excluded  from  the examination.  Following  LA
border  detection  at the end-diastolic  reference  frame,
wall  motion  tracking  was  performed  automatically  in
3D  space throughout  the cardiac  cycle.  The  shape  of
the  LA  was  corrected  if needed.  Due  to the absence  of
an  LA-specific  segmentation  model,  the left atrium  was
automatically  divided  into  16  segments  using  standard  LV
segmentation.9
Using  the  ECG-gated  3D-LA  model,  end-systolic  maximum
volume  (Vmax),  diastolic  volume  before  atrial  contraction
(VpreA)  and  end-diastolic  minimum  volume  (Vmin) were  mea-
sured  in each  case10--16 (Figure  1).  From  the  three  volumes,
the  following  features  of different  phases  of  LA function
were  also  calculated:
For  (systolic)  reservoir  function:
Total  atrial  stroke  volume  (TASV):  Vmax−Vmin
Total  atrial  emptying  fraction  (TAEF):  TASV/Vmax×100
For  (early  diastolic)  conduit  function:
Passive  atrial  stroke  volume  (PASV):  Vmax--VpreA
Passive  atrial  emptying  fraction  (PAEF):  PASV/Vmax×100
For  (late  diastolic)  active  contraction:
Active  atrial  stroke  volume  (AASV):  VpreA−Vmin
Active  atrial  emptying  fraction  (AAEF):  AASV/  VpreA×100
The  following  parameters  of LA deformation  were
assessed13--18: global,  mean  segmental  and  regional  (basal,
mid  and  superior)  radial  (RS), longitudinal  (LS),  circumferen-
tial  (CS),  area  (AS)  and 3D  (3DS) strain.  Using  LA time-strain
curves,  the  first  peak  (feature  of systolic  LA reservoir  func-
tion)  and  the second  peak  (strain  at  atrial  contraction,  a
characteristic  of LA  booster  pump  function)  were  calculated
in  each patient.
Statistical analysis
Continuous  variables  were  presented  as  mean  ±  stan-
dard  deviation  and tested  for  normality.  Categorical  data
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Figure  1  Apical  4-chamber  (A)  and 2-chamber  views  (B),  and  different  parasternal  short-axis  views  at basal  (C3),  mid  (C5)  and
superior (C7)  left  atrial  regions,  extracted  from  the  three-dimensional  volume.  A three-dimensional  wireframe  reconstruction  of  the
left atrium  based  on  three-dimensional  speckle-tracking  echocardiographic  analysis  together  with  volumetric  data  and  segmental
(circumferential) time-strain  curves  are  also  presented.  White,  dashed  and  yellow  arrows  represent  segmental  (systolic)  peak  strain,
(late-diastolic)  strain  at  atrial  contraction  and  global  time-volume  curve,  respectively.  LA:  left  atrium;  LV:  left  ventricle;  RA:  right
atrium; RV:  right  ventricle.
were  expressed  as  percentages.  A  value  of  p<0.05  was
considered  statistically  significant.  Variables  were  com-
pared  using  the independent  samples  Student’s  t test
and  the  chi-square  test  as  appropriate.  Recently,  data
from  the  MAGYAR-Path  Study  confirmed  excellent  intraob-
server  and  interobserver  agreements  for  3D-STE-derived
LA  volumetric  and  strain  data.12,15 MedCalc  software  was
used  for  statistical  calculations  (MedCalc,  Mariakerke,
Belgium).
Results
Clinical characteristics  of light-chain  cardiac
amyloidosis and  hypertrophic  cardiomyopathy
patients
The  prevalence  of  cardiovascular  risk  factors  and medica-
tions  prescribed  in patients  with  AL-CA  and with  HCM  are
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Table  1  Clinical  and  two-dimensional  echocardiographic  characteristics  of  patients  with  light-chain  cardiac  amyloidosis  and
with hypertrophic  cardiomyopathy  and of  controls.
AL-CA  patients  (n=16)  HCM  patients  (n=20)  Controls  (n=16)
Risk  factors
Age  (years)  64.0±9.6  59.8±5.2  58.2±7.2
Male (%)  10  (63)  10  (50)  6  (38)
Diabetes (%)  1  (6) 1 (5)  0  (0)
Hypertension (%)  11  (69)a 11  (55)a 0  (0)
Hypercholesterolemia  (%)  6  (38)a 5 (25)a 0  (0)
Medications
Beta-blockers  (%) 6  (38)a 15  (75)a,b 0  (0)
ACE inhibitors  (%) 8  (50)a 9 (45)a 0  (0)
Diuretics (%) 11  (59)a 5 (25)a,b 0  (0)
2D echocardiography
LA  diameter  (mm)  45.2±6.9a 44.9±4.2a 35.3±3.3
LVEDD (mm)  46.7±5.6  46.0±4.7  47.0±3.4
LVEDV (ml)  110.3±31.9  101.0±28.4  103.5±17.5
LVESD (mm)  29.7±5.3  27.7±4.7  30.1±2.8
LVESV (ml)  41.1±15.7  29.6±11.3b 35.1±6.8
IVS (mm)  14.3±1.8a 21.8±5.4a,b 9.9±2.1
LVPW (mm)  13.7±1.7a 11.9±2.1a,b 10.2±2.1
LVEF (%)  61.3±12.3  70.9±7.2a,b 65.8±4.9
E/A 1.80±1.01  0.93±0.36b 1.07±0.43
3D-STE
Vmax (ml)  79.6±26.6a 78.0±26.6a 55.3±10.7
Vmin (ml)  52.7±23.5a 46.8±21.7  31.9±10.0
VpreA (ml)  69.3±25.0a 66.1±24.1a 45.7±11.4
TASV (ml)  26.8±27.1  35.7±12.3a,b 23.5±5.4
PASV (ml)  10.3±6.3  15.1±7.5  9.7±3.8
AASV (ml)  16.5±24.2  20.6±8.2a,b 13.8±4.8
TAEF (%)  31.2±21.1  37.4±12.3  43.5±10.8
PAEF (%)  13.0±8.2  16.3±9.1  18.2±8.0
AAEF (%) 21.5±20.5a 25.7±9.2  31.1±10.5
2D: two-dimensional; 3D-STE: three-dimensional speckle-tracking echocardiography; AAEF: active atrial emptying fraction; AASV: active
stroke volume; ACE: angiotensin-converting enzyme; AL-CA: light-chain cardiac amyloidosis; HCM: hypertrophic cardiomyopathy; IVS:
interventricular septum; LA: left atrial; LV: left ventricular; LVEDD: left ventricular end-diastolic diameter; LVEDV: left ventricular
end-diastolic volume; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; LVESV: left ventricular end-
systolic volume; LVPW: left ventricular posterior wall; PAEF: passive atrial emptying fraction; PASV: passive atrial stroke volume; TAEF:
total atrial ejection fraction; TASV: total atrial stroke volume; Vmax:  maximum left atrial volume; Vmin: minimum left atrial volume;
VpreA: left atrial volume before atrial contraction.
a p<0.05 vs. controls.
b p<0.05 vs. AL-CA patients.
presented  in Table 1.  Six  of  the 20  HCM  patients  had  a sig-
nificant  (>30  mmHg)  resting  peak LV  outflow  tract gradient
(mean:  83.5±23.0 mmHg),  while  eight  HCM  patients  pre-
sented  systolic  anterior  motion  of the  mitral  valve  anterior
leaflet.  One  HCM patient  had  an implantable  cardioverter-
defibrillator  for prophylaxis  of  malignant  arrhythmia  and
two  HCM  patients  had  previous  percutaneous  translumi-
nal  septal  myocardial  ablation.  Genetic  study  had been
completed  in two  of  the 20  HCM  patients  (10%),  one
of  whom  carried  a  TCAP  gene  mutation  while  the  other
had  no  sarcomeric  gene  mutation.  Genetic  study  of
the  other  patients  is  currently  underway.  Magnetic  res-
onance  imaging  confirmed  the  diagnosis  of HCM in five
cases.
Two-dimensional  echocardiographic data
Standard  2D  echocardiographic  data  are summarized  in
Table  1.  Significant  (grade  ≥2)  MR  was  detected  in seven
HCM  patients  (35%)  and  in two  AL-CA  patients  (13%).
Three-dimensional  speckle-tracking
echocardiography-derived  left atrial
volumetric and volume-based functional
parameters
Increased  LA  volumes  were  demonstrated  in  AL-CA  and
HCM  patients  compared  to  controls.  None  of the LA stroke
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volumes  showed  alterations  in AL-CA  patients,  while  TASV
and  AASV  were  found  to  be  increased  in HCM patients  com-
pared  to  controls  and  AL-CA  patients.  Only  AAEF  was  found
to  be  significantly  reduced  in AL-CA  patients  compared  to
controls.  However,  emptying  fractions  of  HCM  patients  were
between  the  values  of  AL-CA  patients  and those  of  controls.
Three-dimensional speckle-tracking
echocardiography-derived  peak  global,  mean
segmental and  regional left  atrial strain
Peak  global  and  mean  segmental  CS,  LS  and  AS showed  sig-
nificant  reductions  in AL-CA  patients  compared  to  controls
(Table  2). Differences  were  observed  in  certain global  and
mean  segmental  peak  strains  of AL-CA  and HCM patients.
Only  peak  mean  segmental  LS  was  significantly  decreased  in
HCM  patients  compared  to  controls.  Regional  peak  strains
of  age-matched  AL-CA  and HCM patients  and  controls  are
presented  in  Table 2.
Three-dimensional speckle-tracking
echocardiography-derived  global,  mean
segmental and  regional left  atrial strains
at atrial contraction
While  no  differences  were  demonstrated  in  global  and  mean
segmental  strain  at  atrial  contraction  between  HCM  patients
and  controls,  AL-CA  patients  showed reductions  in certain
strain  parameters  compared  to  controls  and  HCM patients.
Results  of detailed  regional  analysis  are  presented  in  Table  3.
Discussion
To  the  best  of  the  authors’  knowledge,  this  is  the first
time  3D-STE-derived  LA  functional  properties  have  been
compared  by  volumetric  and  strain  analysis  between  AL-
CA  and  HCM. Several  features  of  the  three  different  phases
of  LA  function  were  assessed  by  3D-STE  during  the  same
examination:  systolic  reservoir  phase  (by  TASV,  TAEF  and
peak  strains);  early-diastolic  conduit  phase  (by  PASV  and
PAEF);  and  late-diastolic  booster  pump  function  (by  AASV,
AAEF  and strains  at atrial  contraction).  The  present  analy-
sis  showed  different  patterns  of  LA dysfunction:  impairment
of  the  systolic  LA reservoir  phase  occurs  in both  dis-
eases,  because  reduced  peak  strain  was  found  both  in CA
and  HCM,  but  impairment  in LA  active  contraction  phases
occurred  only in  CA  (reductions  in AAEF  and strain  at atrial
contraction).
Several  imaging  methodologies  have  been demonstrated
to  be useful  for  non-invasive  assessment  of LA  dimensions,
volumes  and  function.  3D-STE  is  based  on  a block-matching
algorithm  of  myocardial  speckles  on  the endocardial  border
during  their  frame-to-frame  motion.3,19,20 It  is  a  relatively
new  echocardiographic  technique  that  aims  to incorporate
all  the  benefits  of  STE and  3D  echocardiography,  including
LA  volumetric10--16 and  strain13--18 assessments.
LA  functional  remodeling  in  AL-CA  appears  to  be  more
extensive  than  in HCM.  This  could  be  explained  by  the
fact  that  while  HCM  represents  a myopathic  process  affect-
ing  ventricular  and  atrial  myocardium,  CA results  in much
more  diffuse  and  ubiquitous  involvement,1,2 due  to  mainly
interstitial,  nodular  and branching  deposition  of  amy-
loid,  which  can  have a  major impact  on LV  diastolic
function  that  directly  impairs  LA structure  and  function.
Moreover,  hemodynamic  reasons  could  not  be excluded;
higher  MR  grades  were  detected  in  13-35%  of  AL-CA  and
HCM  patients,  which  could  also  have  an effect  on  atrial
remodeling.
Increased  LA volumes  and  impaired  LA myocardial  defor-
mation  are  well-known  features  in  HCM.13,21 Moreover,
increased  LA volume  is  a  predictor  of  adverse  outcome
and  impaired  LA  function  is  presumed  to  be due  to LV
diastolic  dysfunction  as  a result  of hypertrophy  and  myocar-
dial  fibrosis.22 LA volumes  and  strains  were found  to  be
more  affected  in patients  with  obstruction.22 In  a  recent
3D-STE  study  of  volumetric  and  strain  functional  properties,
only  TAEF  differed  significantly  between  HCM patients  with
vs.  without  grade  ≥2  MR,  but  no  differences  were  found
between  the  same  parameters  in  HCM patients  with  vs.
without  classic  risk  factors.13 On the  other  hand,  LA enlarge-
ment  was  found  to be an independent  predictor  of long-term
mortality,  aiding  risk  stratification  and  management  of
patients  presenting  with  amyloidosis.23 LA dysfunction  was
also  observed  in AL  amyloidosis  patients  without  other
echocardiographic  features  of  cardiac  involvement  using
conventional  and strain  echocardiography  for  measuring  LA
ejection  force,  LA strain  and  strain  rate.24 All these  results
suggest  increased  LA volumes  and  reduced  LA  functional
properties  in  both  HCM  and  CA.  In  the  present  study,  detailed
analysis  of  LA dysfunction  was  performed  by  3D-STE  in
CA and  HCM  patients.  Different  patterns  of  LA dysfunc-
tion  demonstrate  that  3D-STE  theoretically  has  potential
for  differentiating  these  patient  populations.  However,  fur-
ther  studies  in  larger  patient  populations  are warranted  to
confirm  our  findings.
Limitations
Despite  recent  improvements  in 3D  echocardiographic  anal-
ysis,  one  of  the main  limitations  of  3D-STE  is  its relatively
low temporal  and  spatial  resolution  compared  to  2D  tech-
niques.
Although  3D-STE  has  been validated  for the assessment
of  LA  volumes  and  functional  properties  including  strain
assessments  against  different  reference  techniques,10--12,15
further  studies  are  warranted  to  confirm  its  accuracy.  Since
no  2D-STE  or  other  imaging  technique  was  used  together
with  3D-STE  and  no  clinical  or  prognostic  correlations  were
performed  between  these methodologies,  the  accuracy  of
3D-STE  could  not  be established  in this study.
The  diversity  of  HCM  patients,  including  genetic
background,  development  of  dynamic  obstructions  and
arrhythmias,  may  also  have had  an effect  on  the
results.
It  is  important  to emphasize  the  effects  of age  on  LA
parameters.  In  a  recent  study  using  the  same  methodology,
LA functional  properties  of  HCM  patients  were  compared
with  those  of  controls,  and  more  significant  differences  were
found  in volume-based  functional  parameters;  the  mean  age
of  the participants  was  significantly  lower  in this  previous
study.  In the  present  study,  the mean  age of  the control
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Table  2  Comparison  of  three-dimensional  speckle-tracking  echocardiography-derived  global,  mean  segmental  and regional
peak left  atrial  strain  parameters  in  patients  with  cardiac  amyloidosis  and  with  hypertrophic  cardiomyopathy  and  in controls.
AL-CA  patients  (n=16)  HCM patients  (n=20)  Controls  (n=16)
Global  LA  strain  parameters
RS  (%)  -9.7±8.7b -16.5±7.1  -8.8±20.9
CS (%)  11.9±11.1a,b 22.9±15.5  22.5±9.3
LS (%)  11.2±8.4a,b 17.8±7.0  22.2±6.3
AS (%)  22.0±19.6a,b 40.9±28.4  48.1±16.5
3DS (%)  -6.3±6.2 -9.4±5.5  -6.2±13.5
Mean segmental  LA strain  parameters
RS  (%) -13.2±8.4b -20.6±6.8  -11.8±19.7
CS (%) 15.1±10.1a,b 27.1±15.9 26.8±11.5
LS (%) 13.4±8.5a,b 19.7±7.2a 25.3±6.0
AS (%)  28.5±18.4a,b 48.9±28.3  53.4  ±18.0
3DS (%)  -9.8±6.3b -14.3±5.9  -9.0±14.2
Regional LA strain  parameters
Basal  RS  (%)  -10.9±5.81b -17.2±6.0  -11.5±26.3
Mid RS  (%)  -15.0±10.4  -20.8±7.1  -10.3±21.6
Superior RS  (%)  -14.1±13.0b -25.4±14.8a -8.5±22.4
Basal CS  (%)  14.3±12.0a,b 25.2±13.7  32.9±9.5
Mid CS  (%)  13.7±11.2a,b 24.4±16.0  23.7±7.4
Superior CS (%)  18.8±13.1  34.0±29.2  24.9±18.6
Basal LS  (%)  8.5±6.3a,b 14.4±7.2  16.5±8.3
Mid LS  strain  (%)  17.2±11.8a 24.2±9.1a 36.8±11.6
Superior LS (%)  14.8±13.0  21.3±16.1  20.9±9.9
Basal AS  (%)  19.0±13.2a,b 36.7±19.2  46.6±17.4
Mid AS  (%)  31.2±25.2a,b 49.1±25.1  63.4±20.0
Superior AS  (%)  34.8±28.9  66.7±63.9  54.0±39.2
Basal 3DS  (%)  -8.7±4.7b -13.2±5.4  -8.8±21.2
Mid 3DS  (%) -11.0±8.4  -13.5±6.1  -8.2±14.3
Superior 3DS  (%) -9.6±9.1b -17.1±12.0a -6.7±14.5
3DS: three-dimensional strain; AL-CA: light-chain cardiac amyloidosis; AS: area strain; CS:  circumferential strain; HCM: hypertrophic
cardiomyopathy; LA: left atrial; LS: longitudinal strain; RS: radial strain.
a p<0.05 vs. controls.
b p<0.05 vs. HCM patients.
group  was  greater  than in the previous  study,  and  differ-
ences  in  TAEF  and  PAEF  disappeared  due  to  impaired  LA
functional  parameters  of  this older  control  group.13 These
findings  highlight  the importance  of  age  in influencing  the
results.
Only  visual  grading  of  MR  was  used,  which  could  lead  to
misgrading;  other  parameters  were  not  calculated  in this
study.
Moreover,  dependence  on the  place  of  measurement,
even  in  healthy  subjects,  should be  taken  into  account  when
interpreting  results.25
Conclusions
Different  patterns  of  LA functional  characteristics  were
demonstrated  between  AL-CA  and  HCM  patients  by  3D-
STE.  This  may  be  explained  by the different  nature
of  the  diseases:  while  HCM  represents  a  myopathic
process,  AL-CA  results  in much  more  diffuse  and  ubiqui-
tous  involvement  of  the myocardial  tissue  with  amyloid
deposition.
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Table  3  Comparison  of  three-dimensional  speckle-tracking  echocardiography-derived  global,  mean  segmental  and  regional  left
atrial strain  parameters  at  atrial  contraction  in patients  with  cardiac  amyloidosis  and with  hypertrophic  cardiomyopathy  and  in
controls.
AL-CA  patients  (n=16)  HCM  patients  (n=20)  Controls  (n=16)
Global  LA  strain  parameters
RS (%)  -4.4±5.5  -7.2±7.7  -7.9±6.4
CS (%)  5.3±6.5  11.2±10.5  11.0±8.6
LS (%)  3.8±4.3  5.3±4.8  8.0±6.7
AS (%)  9.1±11.0a 17.7±17.1  18.1±13.4
3DS (%)  -2.6±5.3  -5.5±6.3  -5.9±4.6
Mean segmental  LA  strain  parameters
RS (%) -7.5±5.9 -9.7±6.1 -10.5±4.6
CS  (%) 7.2±6.8b 13.4±9.5 11.7±7.6
LS  (%)  6.5±5.2  8.3±6.6  9.3±5.0
AS (%)  11.9±11.0a,b 22.3±16.9  20.1±13.5
3DS (%) -4.9±4.7a -7.2±5.1  -8.22±3.7
Regional LA  strain parameters
Basal RS  (%)  -6.3±4.9a -8.4±4.1  -11.5±5.3
Mid RS  (%)  -7.9  -±  6.4  -9.4±6.0  -10.0±4.3
Superior RS  (%)  -8.9±10.8  -11.9±12.0  -9.6±7.6
Basal CS  (%)  7.9±8.5a,b 15.0±8.8  16.4±8.4
Mid CS  (%)  6.3±6.6  10.5±8.4  10.0±7.3
Superior CS  (%)  7.8±7.1  15.8±18.2  7.9±14.5
Basal LS  (%)  2.8±3.0a,b 6.4±4.3  7.2±6.1
Mid LS  (%)  8.7±7.3  8.6±3.9  11.9±7.9
Superior LS  (%)  7.3±7.5  8.5±14.0  8.6±6.5
Basal AS  (%)  9.6±9.1a,b 20.9±12.9  21.0±9.5
Mid AS  (%)  13.0±13.0  19.2±11.3  23.2±15.1
Superior AS  (%)  13.4±14.9  29.2±43.5  17.4±28.7
Basal 3DS  (%) -4.5±3.8a -6.8±4.3a -10.8±4.5
Mid 3DS  (%) -5.2±5.6 -6.7±5.1  -6.4±3.0
Superior 3DS  (%) -5.2±7.9  -8.8±9.5  -7.2±6.2
3DS: three-dimensional strain; AL-CA: light-chain cardiac amyloidosis; AS: area strain; CS: circumferential strain; HCM: hypertrophic
cardiomyopathy; LA: left atrial; LS: longitudinal strain; RS: radial strain.
a p<0.05 vs. controls.
b p<0.05 vs. HCM patients.
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